Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

The study is a Phase 2 clinical trial of the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas. The study is being conducted in Spain and is expected to enroll approximately 25 patients in total. The primary objective of this Phase 2 study is to evaluate the efficacy of treatment with cirtuvivint. Cirtuvivint is an anti-cancer medication developed by the U.S. company Biosplice Therapeutics, Inc. This drug is an inhibitor of the enzymes CLK1-4 and DYRK1-4 (molecules involved in the cell cycle) and is administered as oral tablets. This product is still under investigation and has not yet been approved in Europe.

NCT Number	NCT07032285
Lead Sponsor	Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas Collaborators: TenaRx, Inc.
Conditions	Soft Tissue Sarcoma (STS)
Enrollment	25 participants
Start Date	2025-01-15
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-06